aod9604 phase 2 trial weight loss results AOD 9604: Peptide Claims vs Clinical Reality AOD 9604 is marketed as a fat-metabolism peptide derived from a growth hormone fragment, often positioned as “HGH-like” without HGH's side effects. The clinical question AOD 9604 dosage: complete protocol
Description
Instead, you might notice slightly less appetite suppression, marginally slower weight loss progress , or a modest increase in blood glucose
Both options work well, but they suit different needs
Clinical studies show that while GLP-1 peptides like semaglutide and tirzepatide primarily reduce fat mass, some lean muscle is lost as well
Concomitant deficiencies (iron, folate), chronic illness, or drug interactions may blunt clinical response and warrant further evaluation
